Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 5OTHER 4OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Ovarian Epithelial 1

Interventions

Radiotherapy 10Cisplatin 10Carboplatin 7Capecitabine 6Neoadjuvant Therapy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Paclitaxel 4Cyclophosphamide 4Trastuzumab 3Tamoxifen 3Surgical Procedures, Operative 3Radiation 3Oxaliplatin 3Hydralazine 3Etoposide 3Drug Therapy 3pertuzumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2endostar protein 2Valproic Acid 2Tranexamic Acid 2Temozolomide 2TP protocol 2Saline Solution 2Radiotherapy, Adjuvant 2Proton Pump Inhibitors 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × OTHER_GOV × fluzoparib × Clear all
NCT06539091 2024-08-06

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

Anhui Provincial Hospital

Phase 3 Not yet recruiting
51 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡